Remove Innovation Remove Obesity Remove Pharmacology
article thumbnail

National AFib Awareness Month: A Call to Action for Physicians Worldwide

ADN Center of Excellence

Factors such as aging populations, rising rates of obesity, hypertension, and other cardiovascular conditions contribute to this increase. From advances in pharmacological treatments to innovative procedures like catheter ablation, the landscape of AFib treatment is continually evolving.

AFIB 59
article thumbnail

Study in JAHA Links Hello Heart Usage to Significant Reductions in Blood Pressure, Cholesterol, and Weight

DAIC

Hypertension, high cholesterol, and obesity are among the most common risk factors of cardiovascular disease and mortality — but getting these risk factors under control can be very challenging,” said Edo Paz, MD , the study’s lead author and SVP, Medical Affairs, Hello Heart. Of 102,475 participants, 49.1% were female.

article thumbnail

American College of Cardiology ACC.24 Late-breaking Science and Guidelines Session Summary

DAIC

24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 Atrial Fibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24